We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Recommends J&J Subsidiary’s Invokana Drug for Type 2 Diabetes
NICE Recommends J&J Subsidiary’s Invokana Drug for Type 2 Diabetes
The UK’s National Institute for Health and Care Excellence (NICE) said it will cover Johnson & Johnson subsidiary Janssen-Cilag’s diabetes drug Invokana (canagliflozin) as a treatment for people with type 2 diabetes.